Psilocybine (Dutch Wikipedia)

Analysis of information sources in references of the Wikipedia article "Psilocybine" in Dutch language version.

refsWebsite

Global rank Dutch rank

41nih.gov

4^th place

12^th place

29doi.org

2^nd place

8^th place

8web.archive.org

1^st place

3elsevier.com

610^th place

1,231^st place

2jamanetwork.com

2,650^th place

2,513^th place

1rovereto.tn.it

low place

1jstor.org

26^th place

170^th place

1clinicaltrials.gov

5,225^th place

2,839^th place

1businesswire.com

615^th place

1,891^st place

1compasspathways.com

low place

1google.ca

838^th place

828^th place

1medpagetoday.com

9,274^th place

low place

1theguardian.com

12^th place

24^th place

1drweil.com

low place

businesswire.com

(en) FDA grants Breakthrough Therapy Designation to Usona Institute's psilocybin program for major depressive disorder. www.businesswire.com (22 november 2019). Geraadpleegd op 20 juli 2020.

clinicaltrials.gov

Psychopharmacology of Psilocybin in Cancer Patients – ClinicalTrials.gov. U.S. National Institutes of Health. 2009. Link geplaatst 2009-09-29.

compasspathways.com

(en) COMPASS Pathways receives FDA Breakthrough Therapy designation for psilocybin therapy for treatment-resistant depression - Compass Pathways. https://compasspathways.com/ (23 oktober 2018). Geraadpleegd op 20 juli 2020.

doi.org

dx.doi.org

Fusar-Poli P, Borgwardt S. (2008). "Albert Hofmann, the father of LSD (1906–2008)". Neuropsychobiology 58 (1): 53–54. DOI:10.1159/000157779 PMID 18799895.
Wurst MM, Semerdzieva M, Vokoun J. (1984). "Analysis of psychotropic compounds in fungi of the genus Psilocybe by reversed-phase high performance liquid chromatography". Journal of chromatography 286: 229–35. DOI:10.1016/S0021-9673(01)99190-3.
Keller T, Schneider A, Regenscheit P, Dirnhofer R, Rücker T, Jaspers J, Kisser W. (1999). "Analysis of psilocybin and psilocin in Psilocybe subcubensis Guzmán by ion mobility spectrometry and gas chromatography-mass spectrometry". Forensic Science International 99 (2): 93–105. DOI:10.1016/S0379-0738(98)00168-6. PMID 10077856.
Bigwood J, Beug MW. (1982). "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (Earle) Singer". Journal of Ethnopharmacology 5 (3): 287–91. DOI:10.1016/0378-8741(82)90014-9. PMID 7201054.
Gartz J. (1987). "Occurrence of psilocybin and baeocystin in fruit bodies of Pluteus salicinus". Planta Medica 53 (3): 290–91. DOI:10.1055/s-2006-962710. PMID 17269025.
Stijve T, Kuyper TW. (1985). "Occurrence of psilocybin in various higher fungi from several European countries". Planta Medica 51 (5): 385–87. DOI:10.1055/s-2007-969526. PMID 17342589.
Singer R, Smith AH. (1958). "Mycological investigations on Teonanácatl, the mexican hallucinogenic mushroom. Part II. A taxonomic monograph of "Psilocybe", section Caerulescentes" (1st page preview). Mycologia 50 (2): 262–303. DOI:10.2307/3756197. Link geplaatst 10-15-2009.
Anastos N, Barnett NW, Pfeffer FM. (2006). "Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography". Science & Justice 46: 91–96. DOI:10.1016/S1355-0306(06)71579-9.
Shirota O, Hakamata W, Goda Y. (2003). "Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of 'magic mushroom'". Journal of Natural Products 66 (6): 885–87. DOI:10.1021/np030059u. PMID 12828485.
Beug MW, Bigwood J. (1981). "Quantitative analysis of psilocybin and psilocin in Psilocybe baeocystis by high performance liquid chromatography and by thin layer chromatography". Journal of chromatography 207: 379–85. DOI:10.1016/S0021-9673(00)88741-5.
Keller T, Schneider A, Regenscheit P, Dirnhofer R, Rucker T, Jaspers J, Kisser W. (1999). "Analysis of psilocybin and psilocin in Psilocybe subcubensis GUZMAN by ion mobility spectrometry and gas chromatography-mass spectrometry". Forensis Science International 99: 93–105. DOI:10.1016/S0379-0738(98)00168-6.
Pedersen-Bjergaard S, Sannes E, Rasmussen K, Tonneson F. (1997). "Determination of psilocybin in Psilocybe semilanceata by capillary zone electrophoresis". Journal of Chromatography 694: 375–81. DOI:10.1016/S0378-4347(97)00127-8.
Wurst M, Kysilka R, Koza T. (1992). "Analysis and isolation of indole alkaloids of fungi by high-performance liquid chromatography". Journal of Chromatography 593: 201–208. DOI:10.1016/0021-9673(92)80287-5.
Saito K, Toyo'oka T, Fukushima T, Kato M, Shirota O, Goda Y. (2004). "Determination of psilocin in magic mushrooms and rat plasma by liquid chromatography with fluorimetry and electrospray ionization mass spectrometry". Analytica Chimica Acta 527: 149–56. DOI:10.1016/j.aca.2004.08.071.
Lindenblatt H, Kramer E, Holzmann-Erens, Gouzoulis-Mayfrank E, Kovar K. (1998). "Quantitation of psilocin in human plasma by high performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction". Journal of Chromatography 709: 255–63. DOI:10.1016/S0378-4347(98)00067-X.
Repke D, Leslie D, Mandell D, Kish N. (1977). "GLC-mass spectral analysis of psilocin and psilocybin". Journal of Pharmaceutical Sciences 66: 743–44. DOI:10.1002/jps.2600660539.
Albers C, Köhler H, Lehr M, Brinkmann B, Beike J. (2004). DOI:10.1007/s00414-004-0469-9 "Development of a psilocin immunoassay for serum and blood samples". International Journal of Legal Medicine 118 (6): 326–31. DOI:10.1007/s00414-004-0469-9. PMID 15526212. Links geplaatst 16-11-2009.
Passie T, Seifert J, Schneider U, Emrich HM. (2002). "The pharmacology of psilocybin.". Addiction Biology 7 (4): 357–64. DOI:10.1080/1355621021000005937. PMID 14578010.
Wark C, Galliher JF. (Sept 2009). "Timothy Leary, Richard Alpert (Ram Dass) and the changing definition of psilocybin". The International Journal on Drug Policy: Epub, voorafgaande aan publicatie. DOI:10.1016/j.drugpo.2009.08.004. PMID 19744846.
Husid MS. (2007). "Cluster headache: A case-based review of diagnostic and treatment approaches". Current Pain and Headache Reports 10 (2): 117–25. DOI:10.1007/s11916-006-0022-2. PMID 16539864.
Sewell RA, Halpern JH, Pope HG Jr. (2006). "Response of cluster headache to psilocybin and LSD". Neurology 66 (12): 1920–22. DOI:10.1212/01.wnl.0000219761.05466.43. PMID 16801660.
Nef HM, Möllmann H, Hilpert P, Krause N, Troidl C, Weber M, Rolf A, Dill T, Hamm C, Elsässer A. (2008). "Apical regional wall motion abnormalities reminiscent to Tako-Tsubo cardiomyopathy following consumption of psychoactive fungi". International Journal of Cardiology 134 (1): e39–e41. DOI:10.1016/j.ijcard.2007.12.064.
Chen C-Y, Storr CL, Anthony JC. (2008). "Early-onset drug use and risk for drug dependence problems". Addictive behaviors 34 (3): 319–322. DOI:10.1016/j.addbeh.2008.10.021. PMID 19022584.
Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX. (2007). "Effects of psilocybin on time perception and temporal control of behaviour in humans". Journal of Psychopharmacology (Oxford) 21 (1): 50–64. DOI:10.1177/0269881106065859. PMID 16714323.
Wackermann J, Wittmann M, Hasler F, Vollenweider FX. (2008). "Effects of varied doses of psilocybin on time interval reproduction in human subjects". Neuroscience Letters 435 (1): 51–55. DOI:10.1016/j.neulet.2008.02.006. PMID 18325673.
Griffiths R, Richards W, Johnson M, McCann U, Jesse R. (2008). "Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later". Journal of Psychopharmacology 22 (6): 621–32. DOI:10.1177/0269881108094300. PMID 18593735. Link geplaatst 30-9-2009.
Espiard ML, Lecardeur L, Abadie P, Halbecq I, Dollfus S. (2005). "Hallucinogen persisting perception disorder after psilocybin consumption: a case study". European Journal of Psychiatry 20 (5–6): 458–60. DOI:10.1016/j.eurpsy.2005.04.008. PMID 15963699.
Vollenweider FX, Geyer MA. (2001). "A systems model of altered consciousness: integrating natural and drug-induced psychoses". Brain Research Bulletin 56 (5): 495–507. DOI:10.1016/S0361-9230(01)00646-3. PMID 11750795.

doi.org

(1987). The occurrence of psilocybin and psilocin in Finnish fungi. Journal of Natural Products 50 (4): 741–44. PMID 3430170. DOI: 10.1021/np50052a030.

drweil.com

Weil A (2006–10–16). "Looking for Mushroom Magic?". Link geplaatst 25-4-2009.

elsevier.com

linkinghub.elsevier.com

Keller T, Schneider A, Regenscheit P, Dirnhofer R, Rücker T, Jaspers J, Kisser W. (1999). "Analysis of psilocybin and psilocin in Psilocybe subcubensis Guzmán by ion mobility spectrometry and gas chromatography-mass spectrometry". Forensic Science International 99 (2): 93–105. DOI:10.1016/S0379-0738(98)00168-6. PMID 10077856.
Sticht G, Käferstein H. (2000). "Detection of psilocin in body fluids". Forensic Science International 113 (1-3): 403–7. PMID 10978655. Link geplaatst 11-15-2009.
Wackermann J, Wittmann M, Hasler F, Vollenweider FX. (2008). "Effects of varied doses of psilocybin on time interval reproduction in human subjects". Neuroscience Letters 435 (1): 51–55. DOI:10.1016/j.neulet.2008.02.006. PMID 18325673.

google.ca

books.google.ca

Stamets P. (1996). Psilocybin Mushrooms of the World: An Identification Guide. Berkeley, California: Ten Speed Press. pp. 36–41. ISBN 0-89815-839-7. Link geplaatst 11-11-2009.

jamanetwork.com

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Arch Gen Psychiatry. 2011;68(1):71-78. doi:10.1001/archgenpsychiatry.2010.116. Geraadpleegd 21 juli 2020
(en) Bogenschutz, Ross, Bhattt et al, Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder. jamanetwork.com (24 augustus 2022). Geraadpleegd op 26 augustus 2022.

jstor.org

Singer R, Smith AH. (1958). "Mycological investigations on Teonanácatl, the mexican hallucinogenic mushroom. Part II. A taxonomic monograph of "Psilocybe", section Caerulescentes" (1st page preview). Mycologia 50 (2): 262–303. DOI:10.2307/3756197. Link geplaatst 10-15-2009.

medpagetoday.com

Smith M. "Medical News: Psilocybin Viewed as Therapy or Research Tool". Link geplaatst 15-10-2009.

nih.gov

ncbi.nlm.nih.gov

Fusar-Poli P, Borgwardt S. (2008). "Albert Hofmann, the father of LSD (1906–2008)". Neuropsychobiology 58 (1): 53–54. DOI:10.1159/000157779 PMID 18799895.
Kysilka R, Wurst M. (1989). "High-performance liquid chromatographic determination of some psychotropic indole derivatives". Journal of Chromatography 464 (2): 434–37. PMID 2722990.
Keller T, Schneider A, Regenscheit P, Dirnhofer R, Rücker T, Jaspers J, Kisser W. (1999). "Analysis of psilocybin and psilocin in Psilocybe subcubensis Guzmán by ion mobility spectrometry and gas chromatography-mass spectrometry". Forensic Science International 99 (2): 93–105. DOI:10.1016/S0379-0738(98)00168-6. PMID 10077856.
Bigwood J, Beug MW. (1982). "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (Earle) Singer". Journal of Ethnopharmacology 5 (3): 287–91. DOI:10.1016/0378-8741(82)90014-9. PMID 7201054.
Borowiak KS, Ciechanowski K, Waloszczyk P. (1998). "Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction". Journal of Toxicology – Clinical Toxicology 36 (1–2): 47–49. PMID 9541042.
Gross ST. (2000). "Detecting psychoactive drugs in the developmental stages of mushrooms". Journal of Forensic Sciences 45 (3): 527–37. PMID 10855955.
Gartz J. (1987). "Occurrence of psilocybin and baeocystin in fruit bodies of Pluteus salicinus". Planta Medica 53 (3): 290–91. DOI:10.1055/s-2006-962710. PMID 17269025.
Stijve T, Kuyper TW. (1985). "Occurrence of psilocybin in various higher fungi from several European countries". Planta Medica 51 (5): 385–87. DOI:10.1055/s-2007-969526. PMID 17342589.
Repke DB, Leslie DT, Guzmán G. (1977). "Baeocystin in Psilocybe, Conocybe and Panaeolus". Lloydia 40 (6): 566–78. PMID 600026.
Horita A, Weber LJ. (1961). "Dephosphorylation of psilocybin to psilocin by alkaline phosphatase". Proceedings of the Society for Experimental Biology 106 (1): 32–33. PMID 13715851.
Shirota O, Hakamata W, Goda Y. (2003). "Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of 'magic mushroom'". Journal of Natural Products 66 (6): 885–87. DOI:10.1021/np030059u. PMID 12828485.
(1987). The occurrence of psilocybin and psilocin in Finnish fungi. Journal of Natural Products 50 (4): 741–44. PMID 3430170. DOI: 10.1021/np50052a030.
Sticht G, Käferstein H. (2000). "Detection of psilocin in body fluids". Forensic Science International 113 (1-3): 403–7. PMID 10978655. Link geplaatst 11-15-2009.
Kysilka R. (1990). "Determination of psilocin in rat urine by high-performance liquid chromatography with electrochemical detection". Journal of Chromatography 534: 287–90. PMID 2094720.
Lindenblatt H, Krämer E, Holzmann-Erens P, Gouzoulis-Mayfrank E, Kovar KA. (1998). "Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction". Journal of Chromatography. B, Biomedical Sciences and Applications 709 (2): 255–63. PMID 9657222.
Grieshaber AF, Moore KA, Levine B. (2001). "The detection of psilocin in human urine". Journal of Forensic Sciences 46 (3): 627–30. PMID 11373000.
Albers C, Köhler H, Lehr M, Brinkmann B, Beike J. (2004). DOI:10.1007/s00414-004-0469-9 "Development of a psilocin immunoassay for serum and blood samples". International Journal of Legal Medicine 118 (6): 326–31. DOI:10.1007/s00414-004-0469-9. PMID 15526212. Links geplaatst 16-11-2009.
Passie T, Seifert J, Schneider U, Emrich HM. (2002). "The pharmacology of psilocybin.". Addiction Biology 7 (4): 357–64. DOI:10.1080/1355621021000005937. PMID 14578010.
Bray JK, Goddard III WA. (2008). "The structure of human serotonin 2c G-protein coupled receptor bound to agonists and antagonists". Journal of Molecular Graphics and Modelling 27: 66–81. PMID 18499489.
Wark C, Galliher JF. (Sept 2009). "Timothy Leary, Richard Alpert (Ram Dass) and the changing definition of psilocybin". The International Journal on Drug Policy: Epub, voorafgaande aan publicatie. DOI:10.1016/j.drugpo.2009.08.004. PMID 19744846.
Moreno FA, Wiegand CB, Taitano EK, Delgado PL. (2006). "Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder". Journal of Clinical Psychiatry 67 (11): 1735–40. PMID 17196053.
Johnson MW, Richards WA, Griffiths RR. (2008). Human hallucinogen research: guidelines for safety. (PDF). Journal of Psychopharmacology 22(6): 603–620. PMID 18593734.
Husid MS. (2007). "Cluster headache: A case-based review of diagnostic and treatment approaches". Current Pain and Headache Reports 10 (2): 117–25. DOI:10.1007/s11916-006-0022-2. PMID 16539864.
Sewell RA, Halpern JH, Pope HG Jr. (2006). "Response of cluster headache to psilocybin and LSD". Neurology 66 (12): 1920–22. DOI:10.1212/01.wnl.0000219761.05466.43. PMID 16801660.
Chen C-Y, Storr CL, Anthony JC. (2008). "Early-onset drug use and risk for drug dependence problems". Addictive behaviors 34 (3): 319–322. DOI:10.1016/j.addbeh.2008.10.021. PMID 19022584.
Peden NR, Macaulay KEC, Bissett AF, Crooks J, Pelosi AJ. (1981). "Clinical toxicology of "magic mushroom" ingestion". Postgraduate Medical Journal 57 (671): 543–45. PMID 7199140.
Isbell H. (1959). "Comparison of the reactions induced by psilocybin and LSD-25 in man". Psychopharmacologia 1: 29–38. PMID 14405870.
Malitz S, Esecover H, Wilkens B, Hoch PH. (1960). "Some observations on psilocybin, a new hallucinogen, in volunteer subjects". Comprehensive psychiatry 1: 8–17. PMID 14420328.
Hollister LE, Prusmack JJ, Paulsen A, Rosenquist N. (1960). "Comparison of three psychotropic drugs (psilocybin, JB-329, and IT-290) in volunteer subjects". Journal of Nervous and Mental Disease 131: 428–34. PMID 13715375.
Rinkel M, Atwell CR, Dimascio A, Brown J. (1960). "Experimental psychiatry. V. Psilocybine, a new psychotogenic drug". New England Journal of Medicine 11 (262): 295–97. PMID 14437505.
Parashos AJ. (1976). "The psilocybin-induced "state of drunkenness" in normal volunteers and schizophrenics". Behavioral Neuropsychiatry 8 (1–12): 83–86. PMID 1052267.
Fischer R, England SM, Archer RC, Dean RK. (1966). "Psilocybin reactivity and time contraction as measured by psychomotor performance". Arzneimittelforschung 16 (2): 180–85. PMID 6014013.
Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX. (2007). "Effects of psilocybin on time perception and temporal control of behaviour in humans". Journal of Psychopharmacology (Oxford) 21 (1): 50–64. DOI:10.1177/0269881106065859. PMID 16714323.
Wackermann J, Wittmann M, Hasler F, Vollenweider FX. (2008). "Effects of varied doses of psilocybin on time interval reproduction in human subjects". Neuroscience Letters 435 (1): 51–55. DOI:10.1016/j.neulet.2008.02.006. PMID 18325673.
Griffiths R, Richards W, Johnson M, McCann U, Jesse R. (2008). "Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later". Journal of Psychopharmacology 22 (6): 621–32. DOI:10.1177/0269881108094300. PMID 18593735. Link geplaatst 30-9-2009.
Espiard ML, Lecardeur L, Abadie P, Halbecq I, Dollfus S. (2005). "Hallucinogen persisting perception disorder after psilocybin consumption: a case study". European Journal of Psychiatry 20 (5–6): 458–60. DOI:10.1016/j.eurpsy.2005.04.008. PMID 15963699.
Mack RB. (1983). "Phenomenally phunny phungi – psilocybin toxicity". New Castle Medical Journal 44: 639–40. PMID 6580536.
Vollenweider FX, Geyer MA. (2001). "A systems model of altered consciousness: integrating natural and drug-induced psychoses". Brain Research Bulletin 56 (5): 495–507. DOI:10.1016/S0361-9230(01)00646-3. PMID 11750795.
Frecska E, Luna LE. (2006). "The adverse effects of hallucinogens from intramural perspective". Neuropsychopharmacol Hungerica 8 (4): 189–200. PMID 17211054.

chem.nlm.nih.gov

Psilocybine bij ChemIDplus

pubmedcentral.nih.gov

Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. (2004). "Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study^{[dode link]}". Psychopharmacology 172 (2): 145–56.

rovereto.tn.it

museocivico.rovereto.tn.it

Guzmán G, Allen JW, Gartz J. (1998). "A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion". Ann. Mus. Civ. Rovereto Sez. 14: 189–280.

theguardian.com

(en) Love, Shayla, "The end-of-life patients finding solace in magic mushrooms: ‘What life after life could be like’", The Guardian, 6 augustus 2024. Geraadpleegd op 18 augustus 2024.

web.archive.org

List of psychotropic substances under international control, Wenen, International Narcotics Control Board, augustus 2003
Moreno FA, Delgado P, Gelenberg AJ. "Effects of Psilocybin in Obsessive-Compulsive Disorder". Multidisciplinary Association for Psychedelic Studies (MAPS). Link geplaatst 2009-09-29.
Recruitment notice for psilocybin clinical trial. Johns Hopkins School of Medicine zoekt vrijwilligers met de diagnose kanker, om deel te nemen aan een wetenschappelijk onderzoek naar zelfonderzoek en persoonlijke betekenis. Link geplaatst 2009-09-29.
Johnson MW, Richards WA, Griffiths RR. (2008). Human hallucinogen research: guidelines for safety. (PDF). Journal of Psychopharmacology 22(6): 603–620. PMID 18593734.
Jerome I. "Warning/Caution". Entheogenic Treatments of Cluster Headaches. Clusterbusters Inc. Link geplaatst 15-10-2009.
Griffiths R, Richards W, Johnson M, McCann U, Jesse R. (2008). "Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later". Journal of Psychopharmacology 22 (6): 621–32. DOI:10.1177/0269881108094300. PMID 18593735. Link geplaatst 30-9-2009.
Recruitment page for Hopkins cancer study
"List of psychotropic substances under international control (International Narcotics Control Board)" (PDF).